Avior Wealth Management’s Prometheus Biosciences, Inc. Common Stock RXDX Stock Holding History

Avior Wealth Management’s Portfolio RXDX Stock Details RXDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-3,434	Closed	-$369K	–	1697
2023 Q1	$369K	Buy	3,434 +1,720	+100%	+$198K	0.03%	420
2022 Q4	$189K	Buy	+1,714	New	+$111K	0.01%	473

Other funds holding RXDX

UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return

FCA

FinTrust Capital Advisors Greenville, South Carolina $591M AUM 26.89% 1-Year Est. Return

Avior Wealth Management's RXDX Position: Q2 2023 in Review

Avior Wealth Management sold out of Prometheus Biosciences, Inc. Common Stock (RXDX) in Q2 2023, closing a stake of 3,434 shares — an estimated $369K sold.

Avior Wealth Management first reported a position in RXDX in Q4 2022 and held it in 2 quarters. The position peaked at $369K in Q1 2023. 2 funds tracked by Wall St. Rank hold RXDX as of Q2 2023.

Avior Wealth Management reported no remaining Prometheus Biosciences, Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
Avior Wealth Management sold 3,434 Prometheus Biosciences, Inc. Common Stock shares in Q2 2023, an estimated $369K.
Avior Wealth Management first reported a position in Prometheus Biosciences, Inc. Common Stock in Q4 2022 and held it in 2 quarters.
Avior Wealth Management's Prometheus Biosciences, Inc. Common Stock position peaked at $369K in Q1 2023.
2 funds tracked by Wall St. Rank held Prometheus Biosciences, Inc. Common Stock as of Q2 2023.

Based on Avior Wealth Management's 13F filing for Q2 2023, filed 19 Jul 2023.